

Research Report

Quipt Home Medical Corp. (QIPT-V / QIPT-Q)
Healthcare

Chelsea Stellick
chelsea.stellick@iagto.ca | 1.403.705.4982

Associate: Paul Stewardson
paul.stewardson@iagto.ca | 1.250.891.9009

QIPT Maintains Strong Operating Performance

Tuesday, August 24, 2021

Event

Yesterday, Quipt Home Medical Corp. (QIPT or the Company) announced the close of an acquisition and its Q3/F21 earnings.

Highlights

- By the numbers.** Quipt reported Q3/F21 revenue growth of 41% YoY (7% organic) to \$26.2M (iA: \$26.7M, cons: \$26.7M) and Adj. EBITDA growth of 21% YoY to \$5.3M (iA: \$5.9M, cons: \$5.9M). Net income of \$6.3M for Q3/F21, Adj. EBITDA margin of 20% including one-time uplisting costs, recurring revenue representing >75% of total revenue, an increase of 65% in resupply set ups/deliveries YoY, and a decrease in bad debt expense to 8% YTD from 10% in Q1-Q3/F20, proves that the underlying business has maintained or improved operating performance through the integration of acquisitions.
- Acquisition.** QIPT made a bolt on acquisition of a business with trailing 12-month annual revenues of ~\$5.5M and Adj. EBITDA of \$1.1M including expected synergies. We note that Quipt recently expanded into Missouri, and this business is in a metro hub in Missouri which will help Quipt achieve scale in this new state. Existing infrastructure and key payor contracts acquired will support expansion in the Missouri market. This acquisition brings QIPT an additional 15,000 active patients and 1,500 prescribers across three locations. The existing operations have a diverse payor mix and a traditional durable medical equipment (DME) product mix.
- Acquisition metrics.** QIPT paid \$2.25M in cash, which is 2.0x Adj. EBITDA post-integration. This is more economical than usual, creating material arbitrage.
- Progress on going national.** QIPT now has 145,000 active patients and 18,500 referring physicians across 60 locations in 15 US states. With \$30.6M cash on hand and \$20M of credit facility availability, we expect ongoing frequent bolt-ons and occasional large acquisitions as QIPT continues its growth trajectory in new and existing states, prioritizing states with high prevalence of COPD like Missouri.
- Model updates.** We have added the acquisition to our model and updated the FX rate to 1.26 (previously 1.25).

Bottom Line


QIPT continues to expand organically and through M&A to build out a national DME platform. The newly acquired entity will consolidate QIPT's position in Missouri with an economical 2.0x EBITDA multiple after synergies which unambiguously creates value. With \$31M cash on hand, access to \$20M of credit, and an active pipeline, we expect more strategic M&A in H2/C21, including larger acquisitions since the recent hiring of David Chester to lead M&A and integration. Strong operating performance confirms that QIPT continues to benefit from operational leverage. We maintain our Buy recommendation and increase our target to \$13.40/share based on an EV/EBITDA valuation, noting that future acquisitions constitute upside to our model.

Rating:	BUY	(unchanged)
Target Price:	C\$13.40 ↑	(from C\$13.00)
Last Price:	C\$7.79	
Ticker:	QIPT-V	

Market Data	
Target return (incl. dist.):	72.0%
Dividend/yield:	C\$0.00 / 0.0%
Shares outstanding (M):	33.2
Market capitalization (C\$M):	259
Enterprise value (C\$M):	208
52-week range (C\$):	4.44 - 10.16
Last Fiscal year end:	Sep. 30, 2020
Average weekly volume:	59,286
Currency (unless otherwise indicated):	USD

Forecast summary	F19A	F20A	F21E	F22E
Revenue (\$M)	63.6	76.8	103.9	134.0
Previous			103.6	129.8
Adj. EBITDA (\$M)	14.8	16.3	22.1	29.5
Previous			22.5	28.6
EPS fd (\$)	(0.08)	(0.06)	(0.09)	0.52
Previous			-0.18	0.53

Key trading multiple	F19A	F20A	F21E	F22E
EV/Revenue	1.0x	1.0x	2.0x	1.6x
EV/adj. EBITDA	14.1x	12.7x	9.4x	7.1x



	Q1	Q2	Q3	Q4	YE
Revenue (\$M)					
F2019	16.1	16.4	15.8	15.3	81.0
F2020	17.9	18.9	20.3	19.6	76.8
F2021	22.8	24.2	26.2	30.6	103.9
F2022	31.9	32.7	33.4	36.0	134.0
Adj. EBITDA (\$M)					
F2019	2.9	3.0	3.0	2.8	11.6
F2020	3.5	3.9	4.4	4.6	16.3
F2021	5.1	5.4	5.3	6.7	22.6
F2022	7.0	7.2	7.3	7.9	29.5
EPS fd (\$)					
F2019	0.0	(0.0)	(0.1)	0.1	(0.1)
F2020	(0.0)	0.0	(0.0)	(0.0)	(0.1)
F2021	0.0	(0.4)	0.2	0.1	(0.1)
F2022	0.1	0.1	0.1	0.2	0.5

shaded values above are iAS forecasts

Company Profile

Quipt Home Medical is a market-leading healthcare services company that aims to improve the home management of chronic illness by providing a diverse offering of home durable medical equipment (DME) and services to patients in the US.

Acquisitions and Geographies

Exhibit 1 provides an overview of the acquisitions QIPT has executed since 2015, along with details of each transaction, updated to include yesterday's acquisition in Missouri.

Exhibit 1: M&A Table


Date	Company	Contribution	Price	Details	
2014	1-Jan	Resource Medical Group, LLC	N/A	\$653,275 and 13,765,842 non-voting Class A Shares	<ul style="list-style-type: none"> Offers an array of DME focused on pulmonary disease services, home-based sleep apnea and chronic obstructive pulmonary disease (COPD) treatments, as well as home-based healthcare logistics and services
	4-Jun	Care Medical Partners, LLC	~\$13M revenue ~\$2M adj. EBITDA	\$5,476,150 or 2.72x trailing 12-months Adj. EBITDA	<ul style="list-style-type: none"> Georgia-based company focused on providing home-based chronic pulmonology services Acquired \$3.15M in medical equipment placed with patients
2015	28-Jan	Black Bear Medical	N/A	N/A	<ul style="list-style-type: none"> Provides home-based healthcare services, including mobility solutions, through several retail locations in Maine and New Hampshire
	10-Mar	West Home Health Care	N/A	~\$11M in cash and the remainder in shares	<ul style="list-style-type: none"> A Virginia-based company focused on providing home-based healthcare services, including mobility solutions for the home Immediately increased revenue by more than 10% and adj. EBITDA by more than 5%
	29-Jul	Legacy Oxygen	~\$3.5M revenue ~\$750K adj. EBITDA	~US\$1.65M in cash and issue 1,708,086 shares	<ul style="list-style-type: none"> Regionally focused company offering home-based medical equipment and services for patients with chronic pulmonary conditions Cross-selling opportunity of existing services to Kentucky locations Expected to increase revenue and EBITDA by more than 5% each before cross-selling opportunities
2018	2-Sep	Patient-Aids Inc.	~\$17M revenue ~\$6.15M adj. EBITDA	~\$32M in cash 2,722,987 PHM common shares	<ul style="list-style-type: none"> High growth and high margin Ohio-based company focused on providing home-based healthcare services 10% increase to annualized revenue, EBITDA margins in excess of 30% and immediately accretive to EPS
	31-Aug	Coastal Med Tech Inc.	~\$4M revenue ~\$1M adj. EBITDA	N/A	<ul style="list-style-type: none"> Bolt-on acquisition focused on providing respiratory services to patients in the Northeast market (5 locations in Maine) CMT had more than 1,500 patients that were actively renting more than 2,000 pieces of equipment annually
	31-Oct	Riverside Medical	N/A	~\$131K cash	<ul style="list-style-type: none"> Provider of home respiratory services and equipment throughout West Tennessee, Southern Middle Tennessee and Northern Mississippi Neighbors PTQ's two largest business units Sells (i) power mobility equipment, vehicle lifts, nebulizers, oxygen concentrators, and CPAP and BiPAP units; (ii) traditional and non-traditional DME respiratory and services; and (iii) non-invasive ventilation equipment, supplies and services
2019		Central Oxygen	N/A	\$230K cash and \$164K in shares issued at \$0.14	<ul style="list-style-type: none"> Expands current operations in Indiana and brings additional insurance contracts Sells (i) nebulizers, oxygen concentrators, and CPAP and BiPAP units; (ii) traditional and non-traditional durable medical respiratory equipment and services; and (iii) non-invasive ventilation equipment, supplies and services.
	15-Oct	Cooley Medical, Inc.	~\$9M revenue ~\$1.6-1.9M adj. EBITDA	~\$3.1M in cash ~\$0.9M in debt	<ul style="list-style-type: none"> Leader and top provider of respiratory services in Eastern and Central Kentucky with six locations More than 13,000 active patients to whom it delivers more than 17,000 pieces of rental equipment annually
	4-Dec	Acadia Medical, Inc.	~\$4M revenue ~\$0.8M adj. EBITDA	~\$2.1M in cash ~\$0.2M in debt	<ul style="list-style-type: none"> Leader and top provider of respiratory services in Maine with four locations
2020	31-Aug	Health Technology Resources, LLC	~\$5.5M Revenue ~\$1.8-2.0M adj. EBITDA	~\$5.4M in cash	<ul style="list-style-type: none"> Focused on high acuity respiratory equipment in the Midwest (namely Chicago). Immediate increase of 3,000 patients to PTQ's current count. NIV RX Plus Disease Transition Program makes up 1/3 of their revenue and was their fastest growing business.
	26-Oct	Sleepwell, LLC	~\$13M in Revenue ~\$3.4-4.0M adj. EBITDA	~\$9.3M in cash and \$5.1M shares issued at \$1.47	<ul style="list-style-type: none"> Sleep therapy business servicing patients in the State of Georgia and in addition it provides sleep services in Dayton, Ohio, representing a new market for Protech. The acquisition will add five new locations and three new markets lifting the Company's active patient count by 15,000.
2021	2-Feb	Mayhugh's Medical Equipment	~\$7M revenue ~\$1.4-1.8M adj. EBITDA	~\$5.8M in cash	<ul style="list-style-type: none"> Leader and top provider of respiratory services in Florida More than 10,000 active patients including 5,000 patients to PTQ's existing subscription-based resupply program
	14-Jul	Three unnamed entities	~\$5.5M Revenue ~\$1.2 adj. EBITDA	\$4.2M in cash	<ul style="list-style-type: none"> 66% respiratory, 33% traditional DME, diverse payor mix, over 10,000 active patients 6 locations across new markets in California, Missouri, Arkansas, and Mississippi
	23-Aug	Unnamed	~\$5.5M Revenue ~\$1.1 adj. EBITDA	\$2.25M in cash	<ul style="list-style-type: none"> Diverse payor mix, traditional DME product mix, 15,000 active patients, 1500 referring physicians 3 locations in a metro hub in Missouri

Source: Quipt Home Medical, Refinitiv, iA Capital Markets

Exhibit 2 illustrates the prevalence of COPD in each US state, which will be a determining factor in where Quipt prioritizes expansion. COPD is particularly prevalent along the Ohio and lower Mississippi Rivers. These states are home to many patients eligible for QIPT's clinical services such as respiratory resupply services, which makes each location (particularly in an urban hub) more efficient through serving a large number of patients.

Exhibit 2: COPD Prevalence by State

Prevalence of Chronic Obstructive Pulmonary Disease (COPD)
for Adults Aged ≥ 18 Years by State, United States,
BRFSS 2019



Source: Center for Disease Control and Prevention

We note the overlap of high acuity COPD areas and Quipt's current network, shown in Exhibit 3.

Exhibit 3: QIPT Operations



Source: Center for Disease Control and Prevention

Valuation & Recommendation

Valuation Summary

Our target price is determined by an EV/Adj. EBITDA valuation approach. Below, we have updated the FX rate for CAD/USD to 1.26 (previously 1.25) and layered the recent acquisition into our estimates.

EV/Adj. EBITDA Valuation. We continue to note that the Company is trading at a significant discount to peers on both an EV/Adj. EBITDA and EV/Revenue basis. We believe the discrepancy is unwarranted given management's strong track record of successfully increasing each acquired businesses' EBITDA margin, its strong recurring revenue model, and its aggressive growth trajectory to achieve \$250M in revenue at 25% EBITDA margins in three to five years. As such, we think that Quipt should trade closer to its comparables on an EV/Adj. EBITDA multiple basis, therefore we use the average of 2021 and 2022 EV/EBITDA multiple from peers to derive an unchanged 13.5x multiple for our valuation. This results in our revised \$13.40/share target price (previously \$13.00/share) and our Buy recommendation.

Exhibit 4: Comps Table

Company	Ticker	Close	Mkt Cap (\$M)	Debt+Pref (\$M)	Ent. Value (\$M)	EBITDA (\$M)			Debt/ EBITDA 21	EV/EBITDA			Revenue			EV/Revenue		
						2020A	2021E	2022E		2020A	2021E	2022E	2020A	2021E	2022E	2020A	2021E	2022E
BIOLASE Inc	BIOL-Q	0.75	110	(26)	84	(14.4)	(13.9)	(7.3)	0.5x	n/a	n/a	n/a	23	37	43	3.7x	2.3x	1.9x
CareRx Corporation*	CRRX-T	6.17	190	81	271	12.9	22.7	42.0	0.3x	21.0x	11.9x	6.5x	168	248	379	1.6x	1.1x	0.7x
Adapthealth Corp	AHCO-O	23.28	3,100	1,726	4,826	189.5	569.2	653.9	0.3x	25.5x	8.5x	7.4x	1,031	2,411	2,735	4.7x	2.0x	1.8x
Dynatronics Corp	DYNT-Q	1.24	20	11	31	n/a	n/a	n/a	n/a	n/a	n/a	n/a	53	47	35	0.6x	0.7x	0.9x
IntriCon Corp	IIN-Q	21.24	190	(26)	164	2.9	8.4	11.8	-0.3x	57.2x	19.7x	14.0x	100	123	139	1.6x	1.3x	1.2x
Amedisys Inc	AMED-O	181.78	5,820	95	5,915	270.4	308.4	334.4	3.3x	21.9x	19.2x	17.7x	2,074	2,257	2,473	2.9x	2.6x	2.4x
Apria Inc.	APR-O	37.78	1,330	181	1,511	n/a	208.6	210.5	1.2x	n/a	7.2x	7.2x	n/a	1,137	1,193	n/a	1.3x	1.3x
Savaria Corp	SIS-T	21.02	1,330	337	1,667	59.6	104.1	128.3	0.3x	28.0x	16.0x	13.0x	354	656	765	4.7x	2.5x	2.2x
Vimed Healthcare Inc	VMD-T	8.31	320	(86)	234	37.2	25.3	31.3	-0.3x	6.3x	9.2x	7.5x	132	113	130	1.8x	2.1x	1.8x
Totals / Average			12,400	255	14,700	560	1,230	1,400	0.7x	26.3x	12.0x	10.5x	3,930	7,030	7,890	3.7x	2.1x	1.9x
Quipt Home Medical (iA)	QIPT-V	7.79	250	(48)	202	16.3	22.6	29.5	-2.1x	12.4x	8.9x	6.9x	76.8	103.9	134.0	2.6x	1.9x	1.5x

*indicates our coverage universe

Source: Quipt Home Medical, Refinitiv, iA Capital Markets

Exhibit 5: Valuation and Target Price

EV/adj. EBITDA Valuation	
NTM Adj. EBITDA (\$M)	26,286
Multiple	13.5x
Enterprise Value (\$M)	354,860
Net cash (debt) end of 2021e (\$M)	4,184
Market Cap (\$M)	359,044
S/O end of F21	33,754
Target Price	\$10.64
USD/CAD FX	1.26
Target Price	\$13.40

Source: iA Capital Markets

Exhibit 6: Financial Snapshot

	F2019 Sep-19	Q1-20 Dec-19	Q2-20 Mar-20	Q3-20 Jun-20	Q4-20 Sep-20	F2020 Sep-20	Q1-21 Dec-20	Q2-21 Mar-21	Q3-21 Jun-21	Q4-21 Sep-21	F2021 Sep-21	F2022 Sep-22	F2023 Sep-23	F2024 Sep-24
Balance Sheet in US\$ thousands														
Current Assets														
Cash and cash equivalents	12,855	6,568	4,877	35,091	30,620	30,620	23,593	27,158	58,416	56,492	56,492	76,982	102,330	132,856
Accounts receivable	12,390	9,251	11,818	9,874	9,523	9,523	9,055	10,870	14,089	15,623	15,623	18,052	21,707	26,006
Other	5,538	5,628	6,988	7,553	7,298	7,298	8,584	10,673	7,600	8,249	8,249	9,430	11,400	13,622
Total Current Assets	30,783	21,448	23,684	52,519	47,441	47,441	41,232	48,701	80,105	80,363	80,363	104,465	135,438	172,484
Asset held for distribution	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Assets														
Property and equipment, net	19,590	19,855	20,522	17,579	17,537	17,537	17,884	18,719	16,458	14,601	14,601	9,748	7,633	7,036
Goodwill	1,881	4,223	4,511	4,324	4,080	4,080	7,962	11,485	11,485	15,685	15,685	15,685	15,685	15,685
Intangible assets, net	2,911	2,057	2,109	1,895	5,845	5,845	10,674	10,337	10,000	9,663	9,663	8,315	9,967	5,619
Total Non Current Assets	24,382	26,135	27,142	23,801	28,066	28,066	37,042	41,027	38,429	40,435	40,435	34,234	33,714	29,838
Total Assets	55,165	47,583	50,825	76,320	75,507	75,507	78,274	89,728	118,534	120,798	120,798	138,699	166,209	201,309
Current Liabilities														
Trade payables and accrued liabilities	10,441	10,117	11,387	9,881	12,341	12,341	9,619	11,633	11,589	12,973	12,973	14,526	16,897	19,689
Financial lease payable	8,528	8,372	6,969	7,762	6,651	6,651	2,362	2,481	2,303	2,570	2,570	3,932	5,967	6,314
Other liabilities	-	-	-	5,966	4,665	4,665	5,319	12,005	12,005	12,005	12,005	12,005	12,005	12,005
Total Current Liabilities	18,969	18,489	18,356	23,610	25,547	25,547	23,494	34,339	33,244	34,024	34,024	33,380	38,893	40,030
Liabilities held for distribution	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Liabilities														
Long-term finance lease obligations	3,081	4,093	6,069	4,396	6,240	6,240	3,704	3,321	9,560	8,000	8,000	10,086	9,511	8,793
Debtentures	13,968	11,543	9,541	12,143	13,545	13,545	14,193	17,327	17,327	17,327	17,327	17,327	17,327	17,327
Deferred tax liability	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	189	191	196	587	587	2,994	1,577	1,377	1,177	1,177	377	-	-
Total Non Current Liabilities	17,047	15,825	15,800	16,735	20,372	20,372	21,494	23,295	29,334	27,574	27,574	28,860	27,908	27,190
Total Liabilities	36,016	34,314	34,156	40,345	45,919	45,919	44,988	57,634	62,578	61,598	61,598	62,240	66,801	67,221
Shareholders' Equity														
Total Shareholders' Equity	19,149	13,270	16,669	35,975	29,588	29,588	33,286	32,094	55,956	59,200	59,200	76,458	101,409	134,089
Total Liabilities & Shareholders' Equity	55,165	47,583	50,825	76,320	75,507	75,507	78,274	89,728	118,534	120,798	120,798	138,699	166,209	201,309
Income Statement in US\$ thousands														
Revenue														
Sale of medical equipment and supplies	27,600	7,746	7,937	8,325	9,169	33,177	10,402	10,401	11,239	12,653	44,696	50,008	55,009	60,510
Rental of medical equipment / patient monitoring	35,900	10,137	10,993	11,993	10,479	43,602	12,353	13,839	15,470	17,291	58,953	79,765	100,658	126,595
Total Revenue	63,500	17,883	18,929	20,318	19,648	76,779	22,755	24,240	26,710	29,944	103,649	129,774	155,667	187,105
Cost of Revenue	17,800	4,735	5,107	5,841	5,386	21,070	6,071	6,122	6,945	7,785	26,923	33,741	40,473	48,647
Gross Profit	45,800	13,148	13,823	14,477	14,262	55,709	16,684	18,118	19,765	22,158	76,726	96,032	115,193	138,458
Operating Costs	48,000	13,477	13,688	14,255	13,500	54,920	15,198	16,684	17,033	18,376	67,291	76,326	87,571	103,300
Net income from continuing operations before financing expenses, taxes and discontinued operations	(2,200)	(329)	134	222	668	895	1,430	1,418	2,732	3,783	9,382	19,706	27,623	35,428
Financing expenses	2,790	474	487	236	961	2,158	590	6,296	577	550	8,013	2,496	2,720	2,796
Net income from continuing operations before taxes	(4,990)	(1,381)	1,649	(2,892)	(1,638)	(4,261)	(41)	(12,490)	2,155	3,233	(7,144)	17,210	24,902	32,632
Recovery for income taxes	210	-	35	38	62	135	(1,407)	-	-	-	(1,407)	-	-	-
Net income from continuing operations after taxes and before discontinued operations	(5,200)	(1,381)	1,615	(2,930)	(1,700)	(4,396)	1,366	(12,490)	2,155	3,233	(5,737)	17,210	24,902	32,632
Discontinued operations	1,910	-	(327)	-	(583)	(910)	-	-	-	-	(910)	(583)	(583)	-
Net income	(3,290)	(1,381)	1,288	(2,930)	(2,011)	(5,034)	1,366	(12,490)	2,155	3,233	(5,737)	17,210	24,902	32,632
Net income per share														
Basic – continuing operations	(0.08)	(0.02)	0.02	(0.03)	(0.02)	(0.06)	0.05	(0.43)	0.07	0.10	(0.18)	0.53	0.76	1.00
Diluted – continuing operations	(0)	(0.02)	0.02	(0.03)	(0.02)	(0)	0.04	(0.43)	0.07	0.10	(0.18)	0.53	0.76	1.00
Weighted average number of common shares outstanding														
Basic	82,860	83,589	83,657	84,261	90,884	83,589	28,177	29,294	32,684	32,684	32,684	32,684	32,684	32,684
Diluted	82,860	83,589	88,496	84,261	90,884	90,884	30,466	29,294	32,684	32,684	32,684	32,684	32,684	32,684
Cash Flow Statement in US\$ thousands														
Operating Activities														
Net income from continuing operations	(9,141)	(1,381)	1,615	(2,930)	(1,700)	(4,396)	1,366	(12,490)	2,155	3,233	(5,737)	17,210	24,902	32,632
Adjustments to reconcile net loss														
Items not affecting cash	21,283	5,291	5,397	6,016	5,782	22,487	6,130	10,833	4,806	4,538	27,713	16,223	14,013	13,133
Change in Working Capital	(5,060)	(997)	(3,470)	4,805	(5,239)	(4,900)	(5,793)	(2,064)	(1,851)	(2,531)	(12,239)	(9,437)	(10,642)	(11,126)
Cash Flow from Operating Activities	8,913	3,491	1,214	10,494	(1,352)	13,848	3,090	3,535	5,109	5,239	16,974	23,996	28,273	34,639
Investing Activities														
Cash Flow from Investing Activities	2,339	(3,229)	34	(299)	(4,808)	(8,302)	(6,873)	(1,822)	(534)	(4,799)	(14,028)	(2,595)	(3,113)	(3,742)
Financing Activities														
Cash Flow from Financing Activities	(5,060)	(3,911)	(3,194)	20,356	1,417	14,669	(2,573)	1,611	26,683	(2,365)	23,356	(910)	188	(371)
Net change in cash and cash equivalents	6,192	(3,648)	(1,945)	30,551	(4,742)	20,214	(6,356)	3,324	31,258	(1,924)	26,302	20,491	25,348	30,525
Effect of exchange rate changes on cash held in foreign currencies	174	120	254	(337)	271	309	721	242	-	-	963	-	-	-
Cash, beginning of year	4,331	10,097	6,568	4,877	35,091	10,097	29,227	23,592	27,158	58,416	30,620	56,492	76,982	102,330
Cash and cash equivalents, end of year	12,855	6,568	4,877	35,091	30,620	30,620	23,592	27,158	58,416	56,492	56,492	76,982	102,330	132,856
EBITDA	9,342	3,433	3,796	4,297	4,536	16,062	4,517	5,358	5,864	6,576	22,425	28,502	34,199	41,115
Adj. EBITDA	14,801	3,466	3,868	4,354	4,648	16,337	5,126	5,370	5,876	6,588	22,476	28,550	34,247	41,163
Adj. EBITDA Margin (%)	23%	19%	20%	21%	24%	21%	23%	22%	22%	22%	22%	22%	22%	22%

Note: an exchange rate of 1.2732 CAD/USD was used to restate former financials

Source: Qipt Home Medical, iA Capital Markets

Investment Recommendation Rating System

- Strong Buy:** Expected to provide a substantial return over the next 12 months, with a lower level of risk than comparable investments.
- Buy:** Expected to provide a reasonably positive return over the next 12 months.
- Speculative Buy:** Expected to provide a positive return over the next 12 months, but with a high level of risk, or based on a future uncertain event.
- Hold:** Expected to remain in a trading range near the current share price for the next 12 months.
- Sell:** Expected to deliver a negative return over the next 12 months.
- Under Review:** Currently available information is inadequate to provide an investment rating.
- Tender:** Investors should tender their shares to the current offer.

Company Related Disclosures

Issuer Company	Ticker	Exch.	Disclosures
CareRx Corp.	CRRX	T	3
Quipt Home Medical Corp	QIPT	V / Q	3

See legend of Disclosures below.

Rating & Target Price History



Source: iA Capital Markets, Bluematrix, Refinitiv

General Disclosures

Please note that Industrial Alliance Securities Inc. merged with MGI Securities Inc. on April 1, 2014 and continued their operations as Industrial Alliance Securities Inc. As a result, the enclosed disclosures may relate to either Industrial Alliance Securities Inc. or to MGI Securities Inc. for the period prior to April 1, 2014. All appropriate disclosure will be included until no longer needed.

The information and opinions contained in this report were prepared by iA Capital Markets. iA Capital Markets is a trademark, business name and a division of iA Private Wealth Inc. iA Private Wealth Inc. is a wholly owned subsidiary of Industrial Alliance Insurance and Financial Services Inc., a life and health insurance company which operates under the trade name iA Financial Group. Industrial Alliance Insurance & Financial Services Inc. is a TSX Exchange listed company (IAG-T) and as such, iA Capital Markets is an affiliate of Industrial Alliance Insurance & Financial Services Inc. The opinions, estimates and projections contained in this report are those of iA Capital Markets as of the date of this report and are subject to change without notice. iA Capital Markets endeavours to ensure that the contents have been compiled or derived from sources that we believe to be reliable and contain information and opinions that are accurate and complete. However, iA Capital Markets makes no representations or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein and accepts no liability

whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to iA Capital Markets that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security. The reader should not rely solely on this report in evaluating whether or not to buy or sell securities of the subject company.

Definitions

"Research Analyst" means any partner, director, officer, employee or agent of iA Capital Markets who is held out to the public as a research analyst or whose responsibilities to iA Capital Markets include the preparation of any written report for distribution to clients or prospective clients of iA Capital Markets, which includes a recommendation with respect to a security.

"Research Report" means any written or electronic communication that iA Capital Markets has distributed or will distribute to its clients or the general public, which contains an analyst's recommendation concerning the purchase, sale or holding of a security (but shall exclude all government debt and government guaranteed debt).

Conflicts of Interest

The research analyst and or associates who prepared this report are compensated based upon (among other factors) the overall profitability of iA Capital Markets, which may include the profitability of investment banking and related services. In the normal course of its business, iA Capital Markets may provide financial advisory services for the issuers mentioned in this report. iA Capital Markets may buy from or sell to customers the securities of issuers mentioned in this report on a principal basis.

Analyst's Certification

Each iA Capital Markets research analyst whose name appears on the front page of this research report hereby certifies that (i) the recommendations and opinions expressed in the research report accurately reflect the research analyst's personal views about the issuer and securities that are the subject of this report and all other companies and securities mentioned in this report that are covered by such research analyst and (ii) no part of the research analyst's compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed by such research analyst in this report.

Analyst's Ethics

As a condition of employment, analysts are required to adhere to the Code of Ethics and Standards of Professional Conduct of the CFA Institute (formerly Association for Investment Management and Research 'AIMR').

Analyst Trading

iA Capital Markets permits analysts to own and trade in the securities and or the derivatives of the issuer under their research coverage, subject to the following restrictions. No trades can be executed in anticipation of coverage for a period of 30 days prior to the issuance of the report and 5 days after the dissemination of the report to our clients. For a change in recommendation, no trading is allowed for a period of 24 hours after the dissemination of such information to our clients. A transaction against an analyst's recommendation can only be executed for a reason unrelated to the outlook of the stock for the issuer and with the prior approval of the Director of Research and the Chief Compliance Officer.

Research Dissemination Policy

iA Capital Markets makes its research available in electronic and printed formats and makes every effort to disseminate research simultaneously to all eligible clients. Research is available to our institutional clients via Bloomberg, Capital IQ, FactSet, Thomson Reuters as well as through our sales representatives via email. Electronic versions are distributed in PDF format. Additionally, the research is only intended to be distributed in jurisdictions where iA Capital Markets is licensed.

For Canadian Residents: This report has been approved by iA Capital Markets which accepts responsibility for this report and its dissemination in Canada. Canadian clients wishing to effect transactions in any such issuer discussed should do so through a qualified salesperson of iA Capital Markets in their particular jurisdiction.

For US Residents: iA Private Wealth Inc. is not a US broker-dealer and therefore is not governed by US laws, rules or regulations applicable to US broker-dealers. Consequently, the persons responsible for the content of this publication are not licensed in the US as research analysts in accordance with applicable rules promulgated by the US self-regulatory organizations. Any US institutional investor wishing to effect trades in any security referred to herein should contact Industrial Alliance Securities Inc. (USA) Inc., a US broker-dealer affiliate of iA Private Wealth Inc.

Disclosure Legend

1. Within the last 12 months, iA Capital Markets has received compensation for fiscal advisory and M&A services, or provided other investment banking services with respect to the securities of the issuer.
2. iA Capital Markets expects to receive or intends to seek compensation for investment banking services from the issuer covered in this report within the next three months.
3. In the past 12 months, iA Capital Markets has managed or co-managed a public offering of securities for the issuer which may include new issues, underwriting, or agency agreements.
4. iA Capital Markets makes a market in the securities of the issuer.
5. iA Capital Markets beneficially owned 1% or more of the common equity (including derivatives exercisable or convertible within 60 days) of the issuer as of the month end preceding this report.
6. The iA Capital Markets analyst(s), who cover the issuer discussed, members of the research analyst's household, research associate(s) or other individual(s) involved directly or indirectly in producing this report:
 - a. have a long position in its common equity securities.
 - b. have a short position in its common equity securities.
7. The analyst has visited the issuer's operations. No payment or reimbursement was received from the issuer for the associated travel costs.
 - a. have a long position in its common equity securities.
8. In the past 12 months, the issuer is (or has been) a client of iA Capital Markets and received non-banking and non-securities related services for which Industrial Alliance Securities Inc. received or expects to receive compensation.
9. In the past 12 months iA Capital Markets, its officers, directors, or analysts involved in the preparation of this report has provided services to the issuer for remuneration other than normal course investment advisory or trade execution services.
10. An officer or director of iA Capital Markets, outside of the Equity Research Department, or a member of his/her household is an officer or director of the issuer or acts in an advisory capacity to the issuer.
11. The analyst has relied in the preparation of the recommendation on material provided by a third party which will be disclosed on request.

Copyright

All rights reserved. All material presented in this document may not be reproduced in whole or in part, or further published or distributed or referred to in any manner whatsoever, nor may the information, opinions or conclusions contained in it be referred to without in each case the prior express written consent of iA Capital Markets.

iA Private Wealth Inc. is a member of the Canadian Investor Protection Fund and the Investment Industry Regulatory Organization of Canada.

© 2021 iA Private Wealth Inc. All rights reserved.

INVESTED IN YOU.